Related Experiment Video
Updated: May 31, 2026
Point-of-care CRISPR-based Diagnostics with Premixed and Freeze-dried Reagents
Published on: August 16, 2024
Ultrasensitive Wash-Free Homogeneous CRISPR Assay Using Spatial Proximity Chemiluminescence Reporter
Yu Zhang1, Liangwen Hao2, Quanshuang Li3
1Department of Medical Imaging, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200065, China.
This study introduces a novel spatial proximity chemiluminescence (SPC) reporter for CRISPR-Cas12a diagnostics, significantly enhancing sensitivity for point-of-care testing. The SPC-CRISPR platform offers attomolar detection limits and simplified workflows for molecular diagnostics.
Area of Science:
- Molecular Diagnostics
- Biotechnology
- Chemical Biology
Background:
- CRISPR-based diagnostics offer potential for point-of-care (POC) testing but face challenges with sensitivity and workflow complexity.
- Existing CRISPR diagnostic methods often require complex sample preparation and lack sufficient sensitivity for early disease detection.
Purpose of the Study:
- To develop a highly sensitive and simplified CRISPR-based diagnostic platform for POC applications.
- To create a novel reporter system that converts CRISPR-Cas12a activity into a robust, excitation-free chemiluminescent signal.
- To validate the diagnostic performance of the new platform using clinical samples.
Main Methods:
- Development of a spatial proximity chemiluminescence (SPC) reporter system for CRISPR-Cas12a.
- Integration of SPC reporter with CRISPR-Cas12a for attomolar detection limits and enhanced sensitivity.
- Combination with recombinase polymerase amplification for single-tube, highly sensitive assays.
- Validation using clinical samples for HPV16 and cancer-associated microRNA detection.
- Implementation in a portable, microfluidic-based device for sample-to-result diagnostics.
Main Results:
- The SPC-CRISPR system achieved attomolar-level detection limits with a 50,000-fold sensitivity enhancement.
- Demonstrated an 8-log dynamic range suitable for quantitative analysis with minimal sample preprocessing.
- Achieved 99.2% accuracy for HPV16 detection in cervical swabs and 86.4% accuracy for miR-19a in plasma samples.
- The portable device showed 100% concordance with quantitative PCR (qPCR) results.
Conclusions:
- The SPC-CRISPR platform significantly enhances sensitivity and simplifies workflows for molecular diagnostics.
- This technology holds great potential for accurate and accessible point-of-care molecular testing.
- The developed diagnostic device offers a wash-free, homogeneous, and portable solution for sample-to-result analysis.
